| 1 |
Kobayashi T, Hoshi M, Yuasa A, Arai S, Ikeda M, Matsuda H, Kim SW, Hibi T. Cost-Effectiveness Analysis of Tofacitinib Compared with Biologics in Biologic-Naïve Patients with Moderate-to-Severe Ulcerative Colitis in Japan. Pharmacoeconomics 2023. [PMID: 36884164 DOI: 10.1007/s40273-023-01254-x] [Reference Citation Analysis]
|
| 2 |
Ernest-Suarez K, Lu C. Editorial: real-world evidence of tofacitinib and vedolizumab in ulcerative colitis-are we one step closer to better positioning therapies after anti-TNF failure? Aliment Pharmacol Ther 2023;57:733-4. [PMID: 36821750 DOI: 10.1111/apt.17351] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
|
| 3 |
Kutschera M, Novacek G, Reinisch W, Högenauer C, Petritsch W, Haas T, Moschen A, Dejaco C. Tofacitinib in the treatment of ulcerative colitis : A position paper issued by the Inflammatory Bowel Disease Working Group of the Austrian Society of Gastroenterology and Hepatology (ÖGGH). Wien Klin Wochenschr 2023;135:1-13. [PMID: 36454302 DOI: 10.1007/s00508-022-02110-2] [Reference Citation Analysis]
|
| 4 |
Herrera-deGuise C, Serra-Ruiz X, Lastiri E, Borruel N. JAK inhibitors: A new dawn for oral therapies in inflammatory bowel diseases. Front Med (Lausanne) 2023;10:1089099. [PMID: 36936239 DOI: 10.3389/fmed.2023.1089099] [Reference Citation Analysis]
|
| 5 |
Hans A, Battat R, Lukin DJ. Article Topic: Positioning Ulcerative Colitis Therapies in 2022 and Beyond. Curr Gastroenterol Rep 2022;24:157-70. [PMID: 36327029 DOI: 10.1007/s11894-022-00853-6] [Reference Citation Analysis]
|
| 6 |
Tofacitinib-Induktionstherapie bei Colitis ulcerosa kann verlängert werden. Z Gastroenterol 2022;60:1742-1744. [DOI: 10.1055/a-1923-8621] [Reference Citation Analysis]
|
| 7 |
Biedermann L, Dubinsky MC, Vermeire S, Fellmann M, Gardiner S, Hur P, Mundayat R, Panés J, Rubin DT. Health-Related Quality of Life Outcomes With Tofacitinib Treatment in Patients With Ulcerative Colitis in the Open-Label Extension Study, OCTAVE Open. Inflamm Bowel Dis 2022:izac222. [PMID: 36242764 DOI: 10.1093/ibd/izac222] [Reference Citation Analysis]
|
| 8 |
Li W, Zhao T, Wu D, Li J, Wang M, Sun Y, Hou S. Colorectal Cancer in Ulcerative Colitis: Mechanisms, Surveillance and Chemoprevention. Current Oncology 2022;29:6091-6114. [DOI: 10.3390/curroncol29090479] [Reference Citation Analysis]
|
| 9 |
Kahi CJ. Blue Notes. Clin Gastroenterol Hepatol 2022;20:1623-4. [PMID: 35878938 DOI: 10.1016/j.cgh.2022.05.004] [Reference Citation Analysis]
|
| 10 |
Parigi TL, Iacucci M, Ghosh S. Blockade of IL-23: What is in the Pipeline? J Crohns Colitis 2022;16:ii64-72. [PMID: 35553666 DOI: 10.1093/ecco-jcc/jjab185] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 4.0] [Reference Citation Analysis]
|
| 11 |
Ferretti F, Cannatelli R, Monico MC, Maconi G, Ardizzone S. An Update on Current Pharmacotherapeutic Options for the Treatment of Ulcerative Colitis. J Clin Med 2022;11. [PMID: 35566428 DOI: 10.3390/jcm11092302] [Cited by in Crossref: 8] [Cited by in F6Publishing: 2] [Article Influence: 8.0] [Reference Citation Analysis]
|
| 12 |
Taxonera C, Carpio López D, Cabez Manas A, Hinojosa del Val JE. Clinical settings with tofacitinib in ulcerative colitis. Rev Esp Enferm Dig 2022. [DOI: 10.17235/reed.2022.8660/2022] [Reference Citation Analysis]
|
| 13 |
Zhang C, Zhu H, Jie H, Ding H, Sun H. Arbutin ameliorated ulcerative colitis of mice induced by dextran sodium sulfate (DSS). Bioengineered 2021. [PMID: 34783296 DOI: 10.1080/21655979.2021.2005746] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
|
| 14 |
D'Amico F, Magro F, Peyrin-Biroulet L, Danese S. Positioning Filgotinib in the Treatment Algorithm of Moderate to Severe Ulcerative Colitis. J Crohns Colitis 2022;16:835-44. [PMID: 34791103 DOI: 10.1093/ecco-jcc/jjab206] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
|
